Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Equity Average: 2011-2025

Historic Equity Average for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $414.8 million.

  • Adma Biologics' Equity Average rose 97.43% to $414.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $414.8 million, marking a year-over-year increase of 97.43%. This contributed to the annual value of $242.1 million for FY2024, which is 68.61% up from last year.
  • Per Adma Biologics' latest filing, its Equity Average stood at $414.8 million for Q3 2025, which was up 7.49% from $385.9 million recorded in Q2 2025.
  • Adma Biologics' Equity Average's 5-year high stood at $414.8 million during Q3 2025, with a 5-year trough of $100.4 million in Q1 2021.
  • For the 3-year period, Adma Biologics' Equity Average averaged around $233.2 million, with its median value being $171.0 million (2024).
  • Per our database at Business Quant, Adma Biologics' Equity Average fell by 2.93% in 2024 and then spiked by 150.05% in 2025.
  • Over the past 5 years, Adma Biologics' Equity Average (Quarterly) stood at $122.0 million in 2021, then increased by 3.45% to $126.2 million in 2022, then grew by 13.59% to $143.3 million in 2023, then skyrocketed by 102.66% to $290.5 million in 2024, then spiked by 97.43% to $414.8 million in 2025.
  • Its Equity Average was $414.8 million in Q3 2025, compared to $385.9 million in Q2 2025 and $361.2 million in Q1 2025.